SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-188035"
 

Search: onr:"swepub:oai:DiVA.org:umu-188035" > Monoaminoxidase inh...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Monoaminoxidase inhibitors as a cause of serotonin syndrome : a systematic case review based on meta-analytic principles

Truedson, Petra (author)
Umeå universitet,Psykiatri,Sunderby Research Unit
Ott, Michael (author)
Umeå universitet,Avdelningen för medicin
Wikström, H. (author)
Umeå universitet,Psykiatri,Sunderby Research Unit
show more...
Maripuu, Martin (author)
Umeå universitet,Psykiatri
Lindmark, K. (author)
Umeå universitet,Avdelningen för medicin
Werneke, Ursula (author)
Umeå universitet,Psykiatri,Sunderby Research Unit
show less...
 (creator_code:org_t)
2021-08-13
2021
English.
In: European psychiatry. - : Cambridge University Press. - 0924-9338 .- 1778-3585. ; 64:S1, s. S361-S362
  • Journal article (other academic/artistic)
Abstract Subject headings
Close  
  • Serotonin syndrome (SS) is a toxic state characterized by increased serotonin activity. It has been suggested that severe serotonin syndrome usually involves monoaminoxidase inhibitors (MAOIs).ObjectivesTo quantify in how far severe SS is associated with MAOIs.MethodsSystematic review and quantitative analysis of all SS cases published between 1 January 2004 and 31 December 2014. Severe SS was defined as cases, either requiring intensive care or resulting in death. Cases were included if they met the diagnostic criteria for SS according to at least one of the three diagnostic criteria systems (Hunter, Radomski and Sternbach).ResultsOf the 299 included cases, 118 (39%) met the definition for severe SS. Eight cases had insufficient information to enable severity classification. Of the severe cases, 48 (40%) involved a MAOI. Of these, 67% related to psychiatric MAOIs, such as phenelzine and moclobemide and 33% to a somatic MAOI, such as methylene blue and linezolid. Of the remaining 173 non-severe SS cases, 24 cases (13%) involved a MAOI. In these, 12% related to a psychiatric MAOI and 83% to a somatic MAOI. One case (4%) had a combination of both. The odds ratio for MAOI involvement in severe versus non-severe serotonin syndrome was 4.3 (CI 2.4 – 7.5; p < 0.001).ConclusionsIn the majority of published case reports, drugs other than MAOIs are involved in serotonin syndrome, even in severe cases. MAOIs are, however, more common in severe serotonin syndrome than in non-severe cases.Conflict of interestM. Ott: scientific advisory board member of Astra Zeneca, Sweden. U. Werneke: received funding for educational activities on behalf of Norrbotten Region; Astra Zeneca, Eli Lilly, Janssen, Novartis, Otsuka/Lundbeck, Servier, Shire, Sunovion. Others: None

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Psykiatri (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Psychiatry (hsv//eng)

Keyword

Serotonin syndrome
Serotonin toxicity

Publication and Content Type

vet (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Truedson, Petra
Ott, Michael
Wikström, H.
Maripuu, Martin
Lindmark, K.
Werneke, Ursula
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Psychiatry
Articles in the publication
European psychia ...
By the university
Umeå University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view